Advertisement

Neuroborreliosis

  • John J. Halperin
Chapter

Abstract

The term neuroborreliosis encompasses nervous system infection with any borrelia. However, it is typically used to describe nervous system Lyme disease (infection with Borrelia burgdorferi) and the closely related disorders in Europe caused by B. garinii and B. afzelii. Common clinical presentations of these tick-borne infections include one or more of the following: lymphocytic meningitis, cranial neuritis, painful radiculitis, and other forms of mononeuropathy multiplex. Diagnosis rests primarily on serologic testing—two-tier testing in serum and demonstration of intrathecal antibody production, comparing cerebrospinal fluid to serum. Treatment with several weeks of oral doxycycline is effective in most patients with neuroborreliosis with parenteral treatment primarily for severe involvement, particularly with parenchymal central nervous system involvement.

Keywords

Lyme disease Neuroborreliosis Meningitis Cranial neuritis Neuropathy Treatment Diagnosis Borrelia burgdorferi B. afzelii B. garinii Intrathecal antibody 

References

  1. 1.
    Krause PJ, Narasimhan S, Wormser GP, Rollend L, Fikrig E, Lepore T, et al. Human Borrelia miyamotoi infection in the United States. N Engl J Med. 2013;368(3):291–3.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Pritt BS, Mead PS, Johnson DK, Neitzel DF, Respicio-Kingry LB, Davis JP, et al. Identification of a novel pathogenic Borrelia species causing Lyme borreliosis with unusually high spirochaetaemia: a descriptive study. Lancet Infect Dis. 2016;16(5):556–64.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Gelderblom H, Londono D, Bai Y, Cabral ES, Quandt J, Hornung R, et al. High production of CXCL13 in blood and brain during persistent infection with the relapsing fever spirochete Borrelia turicatae. J Neuropathol Exp Neurol. 2007;66(3):208–17.CrossRefPubMedGoogle Scholar
  4. 4.
    Boden K, Lobenstein S, Hermann B, Margos G, Fingerle V. Borrelia miyamotoi-associated neuroborreliosis in immunocompromised person. Emerg Infect Dis. 2016;22(9):1617–20.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Mead PS. Epidemiology of Lyme disease. Infect Dis Clin N Am. 2015;29(2):187–210.CrossRefGoogle Scholar
  6. 6.
    Pediatric Lyme Disease Study Group, Gerber MA, Shapiro ED, Burke GS, Parcells VJ, Bell GL. Lyme disease in children in southeastern Connecticut. N Engl J Med. 1996;335(17):1270–4.CrossRefGoogle Scholar
  7. 7.
    Luft BJ, Steinman CR, Neimark HC, Muralidhar B, Rush T, Finkel MF, et al. Invasion of the central nervous system by Borrelia burgdorferi in acute disseminated infection. JAMA. 1992;267(10):1364–7.CrossRefPubMedGoogle Scholar
  8. 8.
    Garin C, Bujadoux A. Paralysie par les tiques. J Med Lyon. 1922;71:765–7.Google Scholar
  9. 9.
    Reik L Jr, Burgdorfer W, Donaldson JO. Neurologic abnormalities in Lyme disease without erythema chronicum migrans. Am J Med. 1986;81(1):73–8.CrossRefPubMedGoogle Scholar
  10. 10.
    Garro AC, Rutman M, Simonsen K, Jaeger JL, Chapin K, Lockhart G. Prospective validation of a clinical prediction model for Lyme meningitis in children. Pediatrics. 2009;123(5):e829–34.CrossRefPubMedGoogle Scholar
  11. 11.
    Halperin JJ, Golightly M. Lyme borreliosis in Bell’s palsy. Long Island Neuroborreliosis Collaborative Study Group. Neurology. 1992;42(7):1268–70.CrossRefPubMedGoogle Scholar
  12. 12.
    Bremell D, Hagberg L. Clinical characteristics and cerebrospinal fluid parameters in patients with peripheral facial palsy caused by Lyme neuroborreliosis compared with facial palsy of unknown origin (Bell’s palsy). BMC Infect Dis. 2011;11:215.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Halperin JJ. Facial nerve palsy associated with Lyme disease. Muscle Nerve. 2003;28:516–7.CrossRefPubMedGoogle Scholar
  14. 14.
    Ogrinc K, Lusa L, Lotric-Furlan S, Bogovic P, Stupica D, Cerar T, et al. Course and outcome of early European Lyme neuroborreliosis (Bannwarth syndrome): clinical and laboratory findings. Clin Infect Dis. 2016;63(3):346–53.CrossRefPubMedGoogle Scholar
  15. 15.
    Halperin JJ, Luft BJ, Volkman DJ, Dattwyler RJ. Lyme neuroborreliosis—peripheral nervous system manifestations. Brain. 1990;113:1207–21.CrossRefPubMedGoogle Scholar
  16. 16.
    Kalina P, Decker A, Kornel E, Halperin JJ. Lyme disease of the brainstem. Neuroradiology. 2005;47(12):903–7.CrossRefPubMedGoogle Scholar
  17. 17.
    Hopf HC. Peripheral neuropathy in acrodermatitis chronica atrophicans (Herxheimer). J Neurol Neurosurg Psychiatry. 1975;38(5):452–8.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Halperin JJ, Little BW, Coyle PK, Dattwyler RJ. Lyme disease: cause of a treatable peripheral neuropathy. Neurology. 1987;37(11):1700–6.CrossRefPubMedGoogle Scholar
  19. 19.
    England JD, Bohm RP, Roberts ED, Philipp MT. Mononeuropathy multiplex in rhesus monkeys with chronic Lyme disease. Ann Neurol. 1997;41(3):375–84.CrossRefPubMedGoogle Scholar
  20. 20.
    Halperin JJ, Krupp LB, Golightly MG, Volkman DJ. Lyme borreliosis-associated encephalopathy. Neurology. 1990;40:1340–3.CrossRefPubMedGoogle Scholar
  21. 21.
    Halperin JJ. Editorial commentary: neuroborreliosis: what is it, what isn’t it? Clin Infect Dis. 2016;63(3):354–5.CrossRefPubMedGoogle Scholar
  22. 22.
    Klempner MS, Hu LT, Evans J, Schmid CH, Johnson GM, Trevino RP, et al. Two controlled trials of antibiotic treatment in patients with persistent symptoms and a history of Lyme disease. N Engl J Med. 2001;345(2):85–92.CrossRefPubMedGoogle Scholar
  23. 23.
    Krupp LB, Hyman LG, Grimson R, Coyle PK, Melville P, Ahnn S, et al. Study and treatment of post Lyme disease (STOP-LD): a randomized double masked clinical trial. Neurology. 2003;60(12):1923–30.CrossRefPubMedGoogle Scholar
  24. 24.
    Fallon BA, Keilp JG, Corbera KM, Petkova E, Britton CB, Dwyer E, et al. A randomized, placebo-controlled trial of repeated IV antibiotic therapy for Lyme encephalopathy. Neurology. 2008;70:992–1003.CrossRefPubMedGoogle Scholar
  25. 25.
    Berende A, ter Hofstede HJ, Vos FJ, van Middendorp H, Vogelaar ML, Tromp M, et al. Randomized trial of longer-term therapy for symptoms attributed to Lyme disease. N Engl J Med. 2016;374(13):1209–20.CrossRefPubMedGoogle Scholar
  26. 26.
    Dersch R, Sommer H, Rauer S, Meerpohl JJ. Prevalence and spectrum of residual symptoms in Lyme neuroborreliosis after pharmacological treatment: a systematic review. J Neurol. 2016;263(1):17–24.CrossRefPubMedGoogle Scholar
  27. 27.
    Wills AB, Spaulding AB, Adjemian J, Prevots DR, Turk SP, Williams C, et al. Long-term follow-up of patients with Lyme disease: longitudinal analysis of clinical and quality-of-life measures. Clin Infect Dis. 2016;62(12):1546–51.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Hinckley AF, Connally NP, Meek JI, Johnson BJ, Kemperman MM, Feldman KA, et al. Lyme disease testing by large commercial laboratories in the United States. Clin Infect Dis. 2014;59(5):676–81.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Nowakowski J, Schwartz I, Liveris D, Wang G, Aguero-Rosenfeld ME, Girao G, et al. Laboratory diagnostic techniques for patients with early Lyme disease associated with erythema migrans: a comparison of different techniques. Clin Infect Dis. 2001;33(12):2023–7.CrossRefPubMedGoogle Scholar
  30. 30.
    Branda JA, Linskey K, Kim YA, Steere AC, Ferraro MJ. Two-tiered antibody testing for Lyme disease with use of 2 enzyme immunoassays, a whole-cell sonicate enzyme immunoassay followed by a VlsE C6 peptide enzyme immunoassay. Clin Infect Dis. 2011;53(6):541–7.CrossRefPubMedGoogle Scholar
  31. 31.
    Branda JA, Strle K, Nigrovic LE, Lantos PM, Lepore TJ, Damle NS, et al. Evaluation of modified 2-tiered serodiagnostic testing algorithms for early Lyme disease. Clin Infect Dis. 2017;64(8):1074–80.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Mygland A, Ljostad U, Fingerle V, Rupprecht T, Schmutzhard E, Steiner I. EFNS guidelines on the diagnosis and management of European Lyme neuroborreliosis. Eur J Neurol. 2010;17(1):8–16. e1–4.CrossRefPubMedGoogle Scholar
  33. 33.
    Halperin JJ, Shapiro ED, Logigian EL, Belman AL, Dotevall L, Wormser GP, et al. Practice parameter: treatment of nervous system Lyme disease. Neurology. 2007;69(1):91–102.CrossRefPubMedGoogle Scholar
  34. 34.
    Todd SR, Dahlgren FS, Traeger MS, Beltran-Aguilar ED, Marianos DW, Hamilton C, et al. No visible dental staining in children treated with doxycycline for suspected Rocky Mountain spotted fever. J Pediatr. 2015;166(5):1246–51.CrossRefPubMedGoogle Scholar
  35. 35.
    Dressler F, Ackermann R, Steere AC. Antibody responses to the three genomic groups of Borrelia burgdorferi in European Lyme borreliosis. J Infect Dis. 1994;169(2):313–8.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of NeurosciencesOverlook Medical CenterSummitUSA
  2. 2.Sidney Kimmel Medical College of Thomas Jefferson UniversityPhiladelphiaUSA

Personalised recommendations